Details of the Drug

General Information of Drug (ID: DMSQDLE)

Drug Name

Flecainide

Synonyms

flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide

Indication

Disease Entry	ICD 11	Status	REF
Tachyarrhythmias	BC71	Approved	[1], [2]
Paroxysmal atrial fibrillation	BC81.30	Phase 1	[3]
Atrial fibrillation	BC81.3	Investigative	[4]

Therapeutic Class

Antiarrhythmic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

414.34

Topological Polar Surface Area (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3-4 h [5]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Bioavailability: The bioavailability of drug is 90% [5]
Clearance: The clearance of drug is 4.6-12.1 mL/min/kg [5]
Elimination: Approximately 86% of a single oral dose is eliminated in the urine, with 42% as unchanged flecainide and 14% as meta-O-dealkylated flecainide, a similar amount of the meta-O-dealkylated lactam of flecainide, approximately 3% as an unidentified acid metabolite, and <1% as 2 other unknown metabolites [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 13 hours [5]
Metabolism: The drug is metabolized to meta-O-dealkylated flecainide or the meta-O-dealkylated lactam of flecainide [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 12.06707 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.52% [8]
Vd: The volume of distribution (Vd) of drug is 5.0-13.4 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 48.4 mg/mL [6]

Chemical Identifiers

Formula: C17H20F6N2O3
IUPAC Name: N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
Canonical SMILES: C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F
InChI: InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
InChIKey: DJBNUMBKLMJRSA-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3356
ChEBI ID: CHEBI:75984
CAS Number: 54143-55-4
DrugBank ID: DB01195
TTD ID: D03DAP
VARIDT ID: DR00512
INTEDE ID: DR0700
ACDINA ID: D00278

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
E3 ubiquitin-protein ligase COP1 (RFWD2)	TT05DLS	COP1_HUMAN	Modulator	[9]
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Blocker	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Flecainide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Flecainide caused by Sodium bicarbonate mediated altered urine pH.	Acidosis [5C73]	[40]
Tromethamine	DMOBLGK	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Flecainide caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[40]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Flecainide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[41]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Midostaurin.	Acute myeloid leukaemia [2A60]	[42]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Arn-509.	Acute myeloid leukaemia [2A60]	[43]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[44]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Oliceridine.	Acute pain [MG31]	[42]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Flecainide due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[43]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Flecainide due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[43]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Flecainide and Ivabradine.	Angina pectoris [BA40]	[43]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Flecainide and Bepridil.	Angina pectoris [BA40]	[42]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Flecainide and Dronedarone.	Angina pectoris [BA40]	[42]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Flecainide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[45]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Posaconazole.	Aspergillosis [1F20]	[42]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Flecainide and Levalbuterol.	Asthma [CA23]	[46]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Pirbuterol.	Asthma [CA23]	[47]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[43]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[42]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Flecainide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[48]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Retigabine.	Behcet disease [4A62]	[42]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Eribulin.	Breast cancer [2C60-2C6Y]	[42]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Lapatinib.	Breast cancer [2C60-2C6Y]	[42]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Bosutinib.	Breast cancer [2C60-2C6Y]	[43]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[49]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Flecainide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[47]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[46]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[47]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Flecainide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[47]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Sevoflurane.	Corneal disease [9A76-9A78]	[42]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Probucol.	Coronary atherosclerosis [BA80]	[42]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Flecainide and Pasireotide.	Cushing syndrome [5A70]	[42]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Osilodrostat.	Cushing syndrome [5A70]	[43]
SODIUM CITRATE	DMHPD2Y	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Flecainide caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[40]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[42]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Deutetrabenazine.	Dystonic disorder [8A02]	[50]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Flecainide and Ingrezza.	Dystonic disorder [8A02]	[51]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Flecainide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[52]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Solifenacin.	Functional bladder disorder [GC50]	[42]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Flecainide caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[53]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[42]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Flecainide caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[54]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Flecainide caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Saquinavir	DMG814N	Major	Decreased metabolism of Flecainide caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Flecainide caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Flecainide caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Sodium acetate anhydrous	DMH21E0	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Flecainide caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[40]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Flecainide caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[60]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Flecainide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[61]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Flecainide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[59]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Flecainide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[42]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Flecainide caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[43]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Flecainide and Crizotinib.	Lung cancer [2C25]	[62]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Flecainide and Ceritinib.	Lung cancer [2C25]	[42]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Flecainide caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[63]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Flecainide and Osimertinib.	Lung cancer [2C25]	[64]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Flecainide and Selpercatinib.	Lung cancer [2C25]	[43]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Flecainide and Lumefantrine.	Malaria [1F40-1F45]	[59]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Flecainide and Halofantrine.	Malaria [1F40-1F45]	[65]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Flecainide and Hydroxychloroquine.	Malaria [1F40-1F45]	[66]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[43]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Flecainide and Vemurafenib.	Melanoma [2C30]	[42]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Flecainide and Panobinostat.	Multiple myeloma [2A83]	[67]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Flecainide and Siponimod.	Multiple sclerosis [8A40]	[59]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Flecainide and Fingolimod.	Multiple sclerosis [8A40]	[42]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Flecainide and Ozanimod.	Multiple sclerosis [8A40]	[68]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Romidepsin.	Mycosis fungoides [2B01]	[42]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Flecainide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[43]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Flecainide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[42]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[69]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Flecainide caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[70]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Entrectinib.	Non-small cell lung cancer [2C25]	[59]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Flecainide caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[71]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Flecainide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[43]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Flecainide and Lofexidine.	Opioid use disorder [6C43]	[42]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Rucaparib.	Ovarian cancer [2C73]	[42]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Triclabendazole.	Parasitic worm infestation [1F90]	[42]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Pimavanserin.	Parkinsonism [8A00]	[72]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Flecainide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[73]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Flecainide and Lefamulin.	Pneumonia [CA40]	[74]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Degarelix.	Prostate cancer [2C82]	[43]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Flecainide caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[75]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Enzalutamide.	Prostate cancer [2C82]	[43]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Relugolix.	Prostate cancer [2C82]	[43]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Flecainide due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[43]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Flecainide due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[43]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[42]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Flecainide due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[43]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Flecainide due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[43]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Flecainide due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[43]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Flecainide due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[43]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Flecainide due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[43]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Quetiapine.	Schizophrenia [6A20]	[42]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Aripiprazole.	Schizophrenia [6A20]	[59]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Flecainide and Iloperidone.	Schizophrenia [6A20]	[42]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Paliperidone.	Schizophrenia [6A20]	[42]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Flecainide and Amisulpride.	Schizophrenia [6A20]	[76]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Asenapine.	Schizophrenia [6A20]	[42]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Flecainide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[42]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Flecainide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[42]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[43]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Pitolisant.	Somnolence [MG42]	[42]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[42]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Lenvatinib.	Thyroid cancer [2D10]	[42]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Flecainide and Cabozantinib.	Thyroid cancer [2D10]	[43]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Flecainide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[77]
-----------


⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Flecainide 100 mg tablet	100 mg	Oral Tablet	Oral
Flecainide 150 mg tablet	150 mg	Oral Tablet	Oral
Flecainide 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2560).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075442.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
5	Metabolism of flecainide. Am J Cardiol. 1984 Feb 27;53(5):41B-51B. doi: 10.1016/0002-9149(84)90501-0.
6	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10	Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
11	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
12	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
13	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
14	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
15	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
16	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
17	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
19	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
20	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
21	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
25	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
27	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
28	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
29	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
30	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
31	Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.
32	Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
33	The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
34	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
35	Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
36	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
37	Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
38	Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
39	Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
40	Hertrampf R, Gundert-Remy U, Beckmann J, et al "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991): 61-3. [PMID: 1782979]
41	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
42	Canadian Pharmacists Association.
43	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
45	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
46	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
47	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
48	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
49	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
51	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
52	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
53	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
54	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
55	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
56	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
57	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
58	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
59	Cerner Multum, Inc. "Australian Product Information.".
60	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
61	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
62	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
64	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
66	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
67	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
68	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
69	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
70	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
71	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
72	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
73	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
74	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
75	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
76	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
77	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]